Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of LY3009104 in active rheumatoid arthritis on methotrexate background
2010-022504-42Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2010
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of baricitinib in rheumatoid arthritis (RA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: ACR20 response at 12 weeks (combined 4 mg and 8 mg LY3009104 vs placebo). Started Nov 2010; status: completed.
02
Drugs
baricitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-022504-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022504-42.